EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer

Bastiaan M Privé iD, Tim M Govers, Bas Israël, Marcel J R Janssen, Bart J R Timmermans, Steffie M B Peters, Michel de Groot, Patrik Zámecnik, Stan R W Wijn, Alexander Hoepping, J P Michiel Sedelaar, Jelle O Barentsz und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07190-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Bastiaan M Privé und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Bastiaan.prive@ra…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Cost-Benefit Analysis, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm.

Methods

A life-time decision model compared the current standard of care of a MRI driven diagnostic pathway, where men undergo prostate biopsy in case of a Prostate Imaging Reporting and Data System (PI-RADS) scores 3–5, to a strategy incorporating PSMA-PET/CT to potentially avoid unnecessary biopsies. Long-term quality-adjusted life years (QALY) and healthcare costs were calculated for each approach.

Results

In PI-RADS 3 lesions, PSMA-PET/CT improved the per-patient QALY by 0.002 and was borderline cost-effective, with an increased cost of €170-€186 per patient and an incremental cost-effectiveness ratio (ICER) of €56,700-€93,212 per QALY. In PI-RADS 1–2, additional biopsies and over-detection of low-risk prostate cancers led to a per-patient QALY decrease of 0.001 points, a cost increase of €416-€429 per patient and was thus not cost-effective.

Conclusion

The addition of PSMA-PET/CT to MRI in patients with equivocal MRI findings appears to be borderline cost-effective due to biopsy avoidance and a reduced detection of indolent, low-risk tumors. In men with a negative MRI, adding a PSMA-PET/CT does not seem to be cost-effective due to a higher number of unnecessary biopsies and only minor improvement in the detection of clinically significant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyCost-Benefit AnalysisGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedMiddle AgedQuality-Adjusted Life Years

Stichwörter der Autor:innen

Cost-effectivenessPSAPSMAProstate cancermpMRI

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Bastiaan.prive@radboudumc.nl.
  • Department of Radiation Oncology, Erasmus Medical Center, Cancer Institute, Rotterdam, The Netherlands. Bastiaan.prive@radboudumc.nl.
  • Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Medip Analytics, Nijmegen, The Netherlands.
  • Department of Urology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Department of Radiation Oncology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

ORCID-Profile: Bastiaan M Privé

Zitieren

APA

Privé, B. M., Govers, T. M., Israël, B., Janssen, M. J. R., Timmermans, B. J. R., Peters, S. M. B., de Groot, M., Zámecnik, P., Wijn, S. R. W., Hoepping, A., Sedelaar, J. P. M., Barentsz, J. O., van Oort, I. M., de Rooij, M., & Nagarajah, J. (2025). A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07190-6

Vancouver

Privé BM, Govers TM, Israël B, Janssen MJR, Timmermans BJR, Peters SMB, et al. A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07190-6

BibTeX
@article{Priv2025,
  author = {Privé, Bastiaan M and Govers, Tim M and Israël, Bas and Janssen, Marcel J R and Timmermans, Bart J R and Peters, Steffie M B and de Groot, Michel and Zámecnik, Patrik and Wijn, Stan R W and Hoepping, Alexander and Sedelaar, J P Michiel and Barentsz, Jelle O and van Oort, Inge M and de Rooij, Maarten and Nagarajah, James},
  title = {A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07190-6}
}
Kostenlos starten →